NEWS RELEASES

Keyword Search
 
Date Title
Dec 07, 2014Printer Friendly VersionTakeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
Dec 07, 2014Printer Friendly VersionSeattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Dec 06, 2014Printer Friendly VersionSeattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Dec 06, 2014Printer Friendly VersionTakeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
Dec 01, 2014Printer Friendly VersionTakeda’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis
Nov 06, 2014Printer Friendly VersionTakeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting
Oct 09, 2014Printer Friendly VersionFDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma
Sep 29, 2014Printer Friendly VersionSeattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Aug 08, 2014Printer Friendly VersionFDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma
Jun 19, 2014Printer Friendly VersionTakeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Jun 01, 2014Printer Friendly VersionVELCADE® (bortezomib)-based Therapy Significantly Improved Progression-Free Survival Compared to Standard Therapy as Frontline Treatment of Patients with Mantle Cell Lymphoma in Phase 3 Study
May 15, 2014Printer Friendly VersionOrteronel Plus Prednisone Improved Progression Free Survival in Men With Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase 3 Study
Dec 09, 2013Printer Friendly VersionUpdated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Dec 09, 2013Printer Friendly VersionSeattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Dec 07, 2013Printer Friendly VersionAnalysis Suggests Increased Overall Survival with Use of Higher Cumulative Dose of VELCADE® (bortezomib) in Patients with Previously Untreated Multiple Myeloma
Nov 11, 2013Printer Friendly VersionTakeda Announces 118 Abstracts on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Leading Pipeline Compounds to be Presented at 55th American Society of Hematology Annual Meeting
Jul 25, 2013Printer Friendly VersionTakeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based on Interim Analysis
Jun 19, 2013Printer Friendly VersionTakeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
Jun 03, 2013Printer Friendly VersionASCO Presentation Highlights Results of Single Agent Oral MLN9708 in Heavily Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma
Jun 01, 2013Printer Friendly VersionTakeda Highlights Data from Clinical Trial Examining the Use of ADCETRIS® (Brentuximab Vedotin) in Pediatric Patients
May 23, 2013Printer Friendly VersionTakeda Announces Organizational Changes at Millennium: The Takeda Oncology Company
May 23, 2013Printer Friendly VersionTakeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
Apr 07, 2013Printer Friendly VersionMeta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients with Multiple Myeloma
Apr 05, 2013Printer Friendly VersionTakeda and Millennium Announce Approval of ADCETRIS® (Brentuximab Vedotin) in Switzerland
Mar 29, 2013Printer Friendly VersionMillennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer
Jan 24, 2013Printer Friendly VersionSeattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
Jan 23, 2013Printer Friendly VersionMultiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year
Jan 16, 2013Printer Friendly VersionFortune Magazine Names Millennium Among 100 Best Companies To Work For
Dec 10, 2012Printer Friendly VersionMillennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting
Dec 10, 2012Printer Friendly VersionData Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Dec 09, 2012Printer Friendly VersionPresentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma
Dec 09, 2012Printer Friendly VersionMillennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas
Dec 09, 2012Printer Friendly VersionOnce a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1/2 study
Nov 05, 2012Printer Friendly VersionVELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting
Nov 05, 2012Printer Friendly VersionMillennium is #1 in Boston Globe Ranking of Top Largest Employer
Nov 01, 2012Printer Friendly VersionMillennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma
Oct 31, 2012Printer Friendly VersionMillennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin)
Oct 19, 2012Printer Friendly VersionMillennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis
Oct 01, 2012Printer Friendly VersionMillennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell
Sep 25, 2012Printer Friendly VersionSeattle Genetics and Millenium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma
Sep 21, 2012Printer Friendly VersionMillennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year
Jul 20, 2012Printer Friendly VersionMillennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe
Jun 28, 2012Printer Friendly VersionMillennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma
Jun 14, 2012Printer Friendly VersionMillennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma
Jun 04, 2012Printer Friendly VersionClinical Data Presented on Orteronel (TAK-700) Without Steroids in Non-Metastatic Prostate Cancer
Jun 03, 2012Printer Friendly VersionASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma
May 23, 2012Printer Friendly VersionMillennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting
May 07, 2012Printer Friendly VersionMillennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma
Apr 12, 2012Printer Friendly VersionSeattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies
Apr 06, 2012Printer Friendly VersionPresage Biosciences and Millennium Enter Into Cancer Research Agreement
Mar 05, 2012Printer Friendly VersionMillennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Jan 26, 2012Printer Friendly VersionSeattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas
Jan 23, 2012Printer Friendly VersionFDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Jan 19, 2012Printer Friendly VersionFortune Magazine Names Millennium Among 100 Best Companies To Work For
Dec 20, 2011Printer Friendly VersionTakeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
Dec 19, 2011Printer Friendly VersionPresentations Highlight Results of Clinical Data for MLN8237 and VELCADE® in the Treatment of Lymphoma
Dec 13, 2011Printer Friendly VersionSeattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma
Dec 13, 2011Printer Friendly VersionPresentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma
Dec 12, 2011Printer Friendly VersionOverall Survival Benefit with VELCADE® based Therapy in Previously Untreated Multiple Myeloma Patients Maintained after Five Year Follow-Up
Dec 12, 2011Printer Friendly VersionSeattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL
Nov 08, 2011Printer Friendly VersionMore than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting
Nov 01, 2011Printer Friendly VersionFDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE® in Patients with Previously Untreated Multiple Myeloma
Oct 06, 2011Printer Friendly VersionMillennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma
Sep 26, 2011Printer Friendly VersionMillennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting
Sep 16, 2011Printer Friendly VersionMillennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 4th Consecutive Year
Jul 19, 2011Printer Friendly VersionMillennium Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma
Jun 28, 2011Printer Friendly VersionMillennium Announces EMA Acceptance of Marketing Authorization Application for ADCETRIS™ (Brentuximab Vedotin)
Jun 23, 2011Printer Friendly VersionData on MLN8237, an Investigational Aurora a Kinase Inhibitor, Presented at International Lymphoma Conference
Jun 10, 2011Printer Friendly VersionData Presentations Showcase Millennium Leadership in Protein Homeostasis at 16th Congress of the European Hematology Association
Jun 10, 2011Printer Friendly VersionMillennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
Jun 06, 2011Printer Friendly VersionSeattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
Jun 06, 2011Printer Friendly VersionMillennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical Oncology
Jun 06, 2011Printer Friendly VersionNovel Velcade Based Combinations Show High Responses In Heavily Pre-Treated Patients With Relapsed Or Refractory Multiple Myeloma
May 06, 2011Printer Friendly VersionVELCADE Improved Outcomes In Multiple Myeloma Patients After Transplant In Nordic Myeloma Study
May 05, 2011Printer Friendly VersionMillennium Leadership In Proteasome Inhibition Highlighted In Relapsed/Refractory Multiple Myeloma At IMW Meeting
Apr 26, 2011Printer Friendly VersionMillennium Submits Two Supplemental NDAs To FDA For VELCADE
Apr 05, 2011Printer Friendly VersionMillennium Pharmaceuticals and Sunesis Pharmaceuticals Announce Collaboration for Kinase Inhibitors in Oncology
Mar 30, 2011Printer Friendly VersionTop-Line Results Announced Of Pivotal Phase 3 Motesanib Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer Patients
Mar 01, 2011Printer Friendly VersionSeattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL
Feb 04, 2011Printer Friendly VersionJournal of Clinical Oncology Publishes Clinical Trial Results of Velcade Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma
Jan 20, 2011Printer Friendly VersionFortune Magazine Names Millennium Among 100 Best Companies To Work For
Dec 09, 2010Printer Friendly VersionVelcade Induction Followed By Velcade Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients
Dec 07, 2010Printer Friendly VersionSubcutaneous Administration of Single-Agent Velcade Demonstrates Efficacy Consistent with Intravenous Administration
Dec 07, 2010Printer Friendly VersionWeekly Velcade in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma
Dec 06, 2010Printer Friendly VersionOral Presentation Showcases Results Of MLN4924 In Patients With Acute Myeloid Leukemia Or High-Grade Myelodysplastic Syndromes
Dec 05, 2010Printer Friendly VersionSeattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Nov 10, 2010Printer Friendly VersionVELCADE® (Bortezomib) Induction, Maintenance and Subcutaneous Data In Multiple Myeloma To Be Featured In Oral Presentations At American Society of Hematology Annual Meeting
Nov 04, 2010Printer Friendly VersionMillennium and Takeda Announce Advancement of Prostate Cancer Program
Nov 03, 2010Printer Friendly VersionData from Brentuximab Vedotin (SGN-35) Phase I Clinical Trial Published in New England Journal of Medicine
Oct 25, 2010Printer Friendly VersionSeattle Genetics and Millennium to Highlight Brentuximab Vedotin (SGN-35) at the International Symposium on Hodgkin Lymphoma
Oct 11, 2010Printer Friendly VersionSeattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCL
Oct 08, 2010Printer Friendly VersionScience Magazine Ranks Millennium Among Top Biopharma Companies In The World
Sep 27, 2010Printer Friendly VersionSeattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma
Sep 14, 2010Printer Friendly VersionMillennium Sales Force Ranked #1 by Independent Survey of Leading Oncologists
Sep 02, 2010Printer Friendly VersionBlood Publication Shows MLN4924 Preclinical Activity in Lymphoma
Jun 07, 2010Printer Friendly VersionNew Clinical Data on Millennium Solid Tumor Compounds Presented at American Society of Clinical Oncology
Jun 06, 2010Printer Friendly VersionOral Presentations Showcase Impressive Results of Velcade® (bortezomib) Based Therapy in Multiple Myeloma
Jun 05, 2010Printer Friendly VersionSeattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma
Jun 04, 2010Printer Friendly VersionVelcade® (Bortezomib) Data in Relapsed or Refractory Amyloidosis Presented at American Society of Clinical Oncology Annual Meeting
May 24, 2010Printer Friendly VersionSeattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial
May 20, 2010Printer Friendly VersionMillennium Announces VELCADE Presentations and First Data in Solid Tumors for Pipeline Molecules at American Society of Clinical Oncology Annual Meeting
May 10, 2010Printer Friendly VersionTakeda to Co-promote VELCADE® (bortezomib) for Injection in Japan
Apr 29, 2010Printer Friendly VersionJournal of Clinical Oncology Publishes Data on Overall Survival Benefit of Velcade® (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma
Apr 08, 2010Printer Friendly VersionSeattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
Mar 08, 2010Printer Friendly VersionMillennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU
Feb 03, 2010Printer Friendly VersionSeattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
Jan 15, 2010Printer Friendly VersionMolecular Cell Publishes Data on A Novel Form of Enzyme Inhibition of A Protein Homeostasis Target
Jan 04, 2010Printer Friendly VersionFDA Approves Addition of Sustained Overall Survival Benefit to Label for Velcade® (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Dec 15, 2009Printer Friendly VersionSeattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Dec 08, 2009Printer Friendly VersionThe Addition of Velcade® (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients With Non-Hodgkin’s Lymphoma
Dec 06, 2009Printer Friendly VersionVelcade® (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up To 88 Percent In Patients Wwth Previously Untreated Multiple Myeloma
Dec 05, 2009Printer Friendly VersionVelcade® (Bortezomib) For Injection Based Regimens Result In Lower Costs And Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens
Dec 01, 2009Printer Friendly VersionMillennium Launches Interactive Website Of Award-Winning Cancer Initiative
Nov 30, 2009Printer Friendly VersionVelcade® (Bortezomib) for Injection To Be Featured In Plenary Session at American Society of Hematology
Nov 18, 2009Printer Friendly VersionMillennium Initiates First Clinical Trial with The First Oral Proteasome Inhibitor
Oct 21, 2009Printer Friendly VersionMillennium Initiates Phase II Trial For Diffuse Large B-Cell Lymphoma
Oct 01, 2009Printer Friendly VersionMillennium Moves Up Ranking Of Top 10 Biopharma Companies In The World By Science Magazine
Sep 18, 2009Printer Friendly VersionFDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for Velcade® (Bortezomib) for Injection
Sep 11, 2009Printer Friendly VersionMillennium Initiates Phase II Trial of Prostate Cancer Compound
Sep 02, 2009Printer Friendly VersionFDA To Review Supplement Containing Long-Term Survival Data for Velcade® (Bortezomib) For Injection
Jul 07, 2009Printer Friendly VersionCBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
May 31, 2009Printer Friendly VersionIn Clinical Trials Velcade® (Bortezomib) for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients
May 31, 2009Printer Friendly VersionThe Addition of Velcade® (Bortezomib) for Injection to New and Standard Combinations Delivers Promising Results in Patients with Non-Hodgkin’s Lymphoma
May 31, 2009Printer Friendly VersionData Presented on Two Novel Millennium Investigational Oncology Drugs at ASCO
May 19, 2009Printer Friendly VersionVelcade® (Bortezomib) For Injection And Pipeline Data To Be Highlighted At American Society Of Clinical Oncology Annual Meeting
Apr 14, 2009Printer Friendly VersionMillennium To Present Oncology Pipeline Data At Annual American Association For Cancer Research Meeting
Apr 08, 2009Printer Friendly VersionNature Publishes Pre-Clinical Data On An Inhibitor Of A Novel Target Discovered By Millennium
Apr 06, 2009Printer Friendly VersionSeattle Genetics Announces Antibody-Drug Conjugate Collaboration with Millennium
Mar 23, 2009Printer Friendly Version Dr. Nancy Simonian Delivers Keynote At Oncology Summit In Boston
Mar 03, 2009Printer Friendly VersionMillennium Initiates Two Phase Il Trials Of Novel Aurora A Kinase Inhibitor
Feb 23, 2009Printer Friendly VersionData On Velcade® (Bortezomib) For Injection Based Therapies To Be Presented At The International Myeloma Workshop
Feb 11, 2009Printer Friendly VersionIndependent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Dec 08, 2008Printer Friendly VersionContinued Overall Survival Advantage Reported from Pivotal Trial of Velcade® (BORTEZOMIB) for Injection Based Therapy in Patients with Previously Untreated Multiple Myeloma
Dec 08, 2008Printer Friendly VersionProlonged Progression-Free Survival Demonstrated by Velcade® (BORTEZOMIB) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
Dec 07, 2008Printer Friendly VersionNovel Velcade® (Bortezomib) For Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Nov 18, 2008Printer Friendly VersionNew Data Will Be Presented At Ash On Velcade® (Bortezomib) For Injection-Based Therapies In Multiple Myeloma And Non-Hodgkin’s Lymphoma
Oct 22, 2008Printer Friendly VersionMillennium Presents New Data On Investigational Drugs For Novel Cancer Targets At Eortc-Nci-Aacr Symposium
Oct 09, 2008Printer Friendly VersionMillennium Ranks In The Top 10 Best Biopharma Employers In The World By Science Magazine
Sep 17, 2008Printer Friendly VersionMillennium Hires Two Senior Executives
Aug 27, 2008Printer Friendly VersionNew England Journal Of Medicine Publishes Phase III Results Of Velcade® (Bortezomib) For Injection In Previously Untreated Multiple Myeloma Patients
Jul 28, 2008Printer Friendly VersionMILLENNIUM ADVANCES ONCOLOGY PIPELINE
Jun 20, 2008Printer Friendly VersionFDA APPROVES VELCADE® (BORTEZOMIB) FOR INJECTION FOR PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
May 31, 2008Printer Friendly VersionMultiple Clinical Trials of VELCADE® (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
May 31, 2008Printer Friendly VersionVelcade(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients with Newly Diagnosed Multiple Myeloma
May 16, 2008Printer Friendly VersionNew Data Support High Complete Remission Rates With VELCADE® (Bortezomib) For Injection Based Therapies In Patients With Newly Diagnosed Multiple Myeloma
May 14, 2008Printer Friendly VersionTakeda Completes Acquisition of Millennium
May 14, 2008Printer Friendly VersionTakeda Completes Subsequent Offering Period for Shares of Millennium Pharmaceuticals, Inc.
May 09, 2008Printer Friendly VersionTakeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Apr 29, 2008Printer Friendly VersionTakeda and Millennium Announce Early Termination of Hart-Scott-Rodino Waiting Period
Apr 10, 2008Printer Friendly VersionMillennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Apr 10, 2008Printer Friendly VersionTakeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
Mar 17, 2008Printer Friendly VersionMillennium Expands IBD Franchise with Addition of New Development Candidate
Mar 13, 2008Printer Friendly VersionPublication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Mar 12, 2008Printer Friendly VersionEleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation
Mar 10, 2008Printer Friendly VersionCowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation
Feb 28, 2008Printer Friendly Version2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation
Feb 20, 2008Printer Friendly VersionMillennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Feb 07, 2008Printer Friendly VersionMillennium Over-Delivers on 2007 Goals and Financial Guidance
Feb 04, 2008Printer Friendly VersionBIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
Jan 31, 2008Printer Friendly Version2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
Jan 31, 2008Printer Friendly VersionMillennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
Jan 30, 2008Printer Friendly VersionFDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Jan 24, 2008Printer Friendly VersionWachovia 2008 Healthcare Conference to Webcast Millennium Presentation
Jan 04, 2008Printer Friendly VersionMillennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Jan 02, 2008Printer Friendly Version26th Annual JPMorgan Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Dec 28, 2007Printer Friendly VersionMillennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Dec 27, 2007Printer Friendly VersionMillennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference
Dec 21, 2007Printer Friendly VersionMillennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Dec 10, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Dec 09, 2007Printer Friendly VersionPhase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Dec 09, 2007Printer Friendly VersionHighest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Dec 03, 2007Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
Nov 26, 2007Printer Friendly VersionNew Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Nov 20, 2007Printer Friendly VersionPiper Jaffray 19th Annual Healthcare Conference to Webcast Millennium Presentation
Nov 20, 2007Printer Friendly VersionBMO Capital Markets Healthcare Conference to Webcast Millennium Presentation
Nov 06, 2007Printer Friendly VersionMillennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
Nov 05, 2007Printer Friendly Version2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
Nov 01, 2007Printer Friendly VersionMillennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Oct 30, 2007Printer Friendly VersionCIBC World Markets 18th Annual Healthcare Conference to Webcast Millennium Presentation
Oct 25, 2007Printer Friendly VersionMillennium to Webcast Third-Quarter 2007 Financial and Operational Results
Oct 15, 2007Printer Friendly VersionFDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Oct 04, 2007Printer Friendly VersionLife Sciences Leader Joins Millennium Board of Directors
Sep 20, 2007Printer Friendly VersionUBS Global Life Sciences Conference To Webcast Millennium Presentation
Sep 18, 2007Printer Friendly VersionPhase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Sep 13, 2007Printer Friendly VersionMerrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Sep 04, 2007Printer Friendly VersionBear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
Aug 29, 2007Printer Friendly VersionThomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Aug 15, 2007Printer Friendly VersionMillennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Jul 26, 2007Printer Friendly VersionMillennium Highlights Strong Second-Quarter Results and Upcoming Growth Catalysts
Jul 19, 2007Printer Friendly VersionMillennium to Webcast Second-Quarter 2007 Financial and Operational Results
Jul 16, 2007Printer Friendly VersionMillennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Jul 02, 2007Printer Friendly VersionVELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Jun 28, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications Associated with Multiple Myeloma
Jun 28, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Jun 28, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Jun 19, 2007Printer Friendly VersionVELCADE(R) (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
Jun 05, 2007Printer Friendly VersionGoldman Sachs 28th Annual Global Healthcare Conference To Webcast Millennium Presentation
Jun 04, 2007Printer Friendly VersionNew Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Jun 03, 2007Printer Friendly VersionMillennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models
Jun 03, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Jun 03, 2007Printer Friendly VersionVELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Jun 03, 2007Printer Friendly VersionMillennium Advances Aurora A Kinase Program
Jun 01, 2007Printer Friendly VersionBear Stearns 2007 Biotech Confab To Webcast Millennium Presentation
Jun 01, 2007Printer Friendly VersionMillennium Appoints Three New Members to Executive Management Team
May 29, 2007Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection to be Featured at Upcoming American Society of Clinical Oncology Meeting
May 24, 2007Printer Friendly VersionBank of America 2007 Healthcare Conference to Webcast Millennium Presentation
May 17, 2007Printer Friendly VersionCitigroup 2007 Healthcare Conference to Webcast Millennium Presentation
May 17, 2007Printer Friendly VersionMillennium Resumes Clinical Program for MLN0002
May 09, 2007Printer Friendly VersionMillennium to Webcast 2007 Annual Meeting of Stockholders
May 01, 2007Printer Friendly VersionRobert W. Baird 2007 Growth Stock Conference to Webcast Millennium Presentation
Apr 27, 2007Printer Friendly VersionMorgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Apr 26, 2007Printer Friendly VersionMillennium Reports Strong Financial and Operational Results for First Quarter 2007
Apr 19, 2007Printer Friendly VersionMillennium to Webcast First-Quarter 2007 Financial Results
Apr 17, 2007Printer Friendly VersionMillennium Discovers Biomarkers Potentially Predictive of Response to VELCADE® (Bortezomib) for Injection
Apr 06, 2007Printer Friendly VersionCIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Mar 12, 2007Printer Friendly VersionLehman Brothers Tenth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation
Mar 07, 2007Printer Friendly VersionCowen and Company 27th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Feb 08, 2007Printer Friendly VersionMillennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP Net Loss by 78%(1)
Feb 07, 2007Printer Friendly VersionBIO CEO & Investor 2007 Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation
Feb 01, 2007Printer Friendly Version2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation
Jan 04, 2007Printer Friendly VersionMillennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss
Jan 02, 2007Printer Friendly VersionJPMorgan 25th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Dec 29, 2006Printer Friendly VersionMillennium to Webcast Business Update in Advance of 25th Annual JPMorgan Healthcare Conference
Dec 14, 2006Printer Friendly VersionDr. Bob Tepper, President of R&D, to Leave Millennium
Dec 12, 2006Printer Friendly VersionVELCADE® (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Dec 12, 2006Printer Friendly VersionVELCADE® (Bortezomib) for Injection Based Therapies Show Consistently High Complete and Near complete Response Rates in Front-Line Multiple Myeloma Trials
Dec 11, 2006Printer Friendly VersionVELCADE® (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Dec 11, 2006Printer Friendly VersionPositive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Dec 11, 2006Printer Friendly VersionMultiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Dec 10, 2006Printer Friendly VersionVELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Dec 08, 2006Printer Friendly VersionSignificant Data on VELCADE® (bortezomib) For Injection To Be Presented at Upcoming American Society of Hematology Meeting
Dec 08, 2006Printer Friendly VersionFDA Approves VELCADE® (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Dec 04, 2006Printer Friendly VersionPublications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Nov 28, 2006Printer Friendly VersionMillennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Nov 22, 2006Printer Friendly VersionPiper Jaffray Health Care Conference to Webcast Millennium Presentation
Nov 15, 2006Printer Friendly VersionMillennium Closes Sale of $250.0 Million in Convertible Senior Notes
Nov 09, 2006Printer Friendly VersionMillennium Prices $225.0 Million in Convertible Senior Notes
Nov 09, 2006Printer Friendly VersionMillennium Announces Proposed Offering of $200 Million in Convertible Senior Notes
Nov 02, 2006Printer Friendly VersionCIBC World Markets 17th Annual Healthcare Conference to Webcast Millennium Presentation
Oct 30, 2006Printer Friendly VersionMassOpps Investment Conference to Webcast Millennium Presentation
Oct 26, 2006Printer Friendly VersionMillennium Achieves Non-GAAP Profitability and Reduces GAAP Net Loss for Third Consecutive Quarter(1)
Oct 26, 2006Printer Friendly VersionMillennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE® (bortezomib) for Injection
Oct 19, 2006Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Third-Quarter 2006 Financial Results
Oct 17, 2006Printer Friendly VersionMillennium Issues Statement Regarding AnorMED Inc.
Oct 06, 2006Printer Friendly VersionJournal of Clinical Oncology Publishes Final Study Results of VELCADE® (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Sep 26, 2006Printer Friendly VersionMillennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Sep 18, 2006Printer Friendly VersionUBS Global Life Sciences Conference to Webcast Millennium Presentation
Sep 11, 2006Printer Friendly VersionLeerink Swann & Company / MEDACorp Cancer Roundtable Conference to Webcast Millennium Presentation
Sep 05, 2006Printer Friendly VersionBear Stearns 19th Annual Healthcare Conference to Webcast Millennium Presentation
Sep 05, 2006Printer Friendly VersionThomas Weisel Partners Healthcare Conference 2006 to Webcast Millennium Presentation
Aug 30, 2006Printer Friendly VersionMillennium Announces Phase I Trial of MLN0415 for Inflammatory Disorders
Aug 09, 2006Printer Friendly VersionFDA Grants Priority Review to VELCADE® (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma
Jul 27, 2006Printer Friendly VersionMillennium Reports Strong Financial Results and Significant Accomplishment Toward 2006 Goals
Jul 26, 2006Printer Friendly VersionBaird 2006 Focus on Oncology Conference to Webcast Millennium Presentation
Jul 20, 2006Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Second-Quarter 2006 Financial Results
Jun 21, 2006Printer Friendly VersionVELCADE® (Bortezomib) for Injection Showed Unprecedented Results In Newly Diagnosed Multiple Myeloma Patients
Jun 15, 2006Printer Friendly VersionMillennium Responds to Market Report
Jun 09, 2006Printer Friendly VersionMillennium Files sNDA for VELCADE® (Bortezomib) for Injection in Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Jun 06, 2006Printer Friendly VersionGoldman Sachs 27th Annual Healthcare Conference to Webcast Millennium Presentation
Jun 05, 2006Printer Friendly VersionData at ASCO Demonstrate Potential of VELCADE® (Bortezomib) for Injection Across Solid and Hematological Cancers
Jun 04, 2006Printer Friendly VersionAddition of VELCADE® (Bortezomib) for Injection Improved survival in Front-Line Advanced Lung Cancer
Jun 04, 2006Printer Friendly VersionVELCADE® (Bortezomib) for Injection May Offer New Standard of Care in Relapsed/Refractory Mantle Cell Lymphoma
Jun 04, 2006Printer Friendly VersionVELCADE® (Bortezomib) for Injection Demonstrated High Single-Agent Response Rates in Newly Diagnosed Multiple Myeloma Patients
May 31, 2006Printer Friendly VersionMillennium Announces MLN1202 Fully Met Primary Endpoint in Phase II Clinical Study of Patients at High Risk for Atherosclerosis
May 26, 2006Printer Friendly VersionNew Data on VELCADE® (bortezomib) for Injection to be Presented at Upcoming American Society of Clinical Oncology Meeting
May 25, 2006Printer Friendly VersionBear Stearns Biotech Boston Confab to Webcast Millennium Presentation
May 04, 2006Printer Friendly VersionBaird 2006 Growth Stock Conference to Webcast Millennium Presentation
Apr 28, 2006Printer Friendly VersionMorgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Presentation
Apr 27, 2006Printer Friendly VersionMillennium Pharmaceuticals to Webcast 2006 Annual Meeting of Stockholders
Apr 27, 2006Printer Friendly VersionMillennium Achieves First Quarter 2006 Non-GAAP Profitability and Reduces GAAP Net Loss
Apr 20, 2006Printer Friendly VersionMillennium Pharmaceuticals to Ring the NASDAQ Opening Bell in Conjunction with First Quarter 2006 Financial Results Conference Call
Apr 18, 2006Printer Friendly VersionMillennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma
Mar 09, 2006Printer Friendly VersionMillennium Achieves $10 Million Milestone Payment
Mar 06, 2006Printer Friendly VersionMillennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE® (Bortezomib) for Injection in Non-Small Cell Lung Cancer
Mar 02, 2006Printer Friendly VersionLehman Brothers Ninth Annual Global Healthcare Conference to Webcast Millennium Presentation
Feb 27, 2006Printer Friendly VersionSG Cowen & Co. 26th Annual Health Care Conference to Webcast Millennium Presentation
Feb 17, 2006Printer Friendly VersionCitigroup 2006 Healthcare Conference to Webcast Millennium Presentation
Feb 09, 2006Printer Friendly VersionMillennium Announces New Senior Vice President of Human Resources
Feb 06, 2006Printer Friendly VersionMillennium Announces Pharmaceutical Industry Leader Joins the Board Of Directors
Jan 31, 2006Printer Friendly VersionMerrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Millennium Presentation
Jan 26, 2006Printer Friendly VersionMillennium Achieves 2005 Financial Guidance
Jan 25, 2006Printer Friendly VersionMillennium Announces Appointments of Executive Vice President of Commercial Operations, Vice President of Finance and Several Key Promotions
Jan 20, 2006Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Full-Year 2005 Financial Results
Jan 05, 2006Printer Friendly VersionMillennium Details Strategic Drivers for Profitable Growth and 2006 Goals; Highlights 2005 Accomplishments
Jan 05, 2006Printer Friendly VersionJPMorgan 24th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Dec 30, 2005Printer Friendly VersionMillennium to Webcast Business Update in Advance of 24th Annual JPMorgan Healthcare Conference
Dec 13, 2005Printer Friendly VersionConsistently High Complete and Overall Response Rates in Newly-Diagnosed Multiple Myeloma Patients Shown With Velcade®(bortezomib) for Injection Based Therapies
Dec 12, 2005Printer Friendly VersionVELCADE® (bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients
Dec 12, 2005Printer Friendly VersionVELCADE® (bortezomib) for Injection Continues to Show Impressive Results in a Variety of Lymphomas
Dec 11, 2005Printer Friendly VersionNew Data Show Median 30-Month Survival With VELCADE® (Bortezomib) for Injection in Relapsed Multiple Myeloma
Dec 08, 2005Printer Friendly VersionMillennium Announces Webcast of Data on VELCADE® (Bortezomib) for Injection From the 47th Annual Meeting of the American Society of Hematology
Dec 06, 2005Printer Friendly VersionNew Data on VELCADE® (bortezomib) for Injection to Be Presented at Upcoming American Society of Hematology Meeting
Nov 10, 2005Printer Friendly Version2005 Credit Suisse First Boston Health Care Conference to Webcast Millennium Presentation
Nov 03, 2005Printer Friendly VersionMillennium Initiates Trial of Novel Aurora Kinase Inhibitor MLN8054 in Advanced Solid Tumors
Nov 02, 2005Printer Friendly VersionMillennium Announces Clinical Updates at Analyst Day Meeting
Oct 31, 2005Printer Friendly VersionCIBC World Markets Sixteenth Annual Healthcare Conference to Webcast Millennium Presentation
Oct 28, 2005Printer Friendly VersionMassOpps Investment Conference to Webcast Millennium Presentation
Oct 27, 2005Printer Friendly VersionMillennium Announces Webcast of Analyst & Investor Day 2005 Presentations
Oct 26, 2005Printer Friendly VersionMillennium Reports Strong Third Quarter 2005 Financial Results
Oct 20, 2005Printer Friendly VersionMillennium Senior Vice President Abbie Celniker Receives Honors from Massachusetts Technology Leadership Council
Oct 19, 2005Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Third Quarter Financial Results
Oct 17, 2005Printer Friendly VersionMillennium Initiates Combination Phase I/II Trial of MLN518 in Acute Myelogenous Leukemia
Sep 13, 2005Printer Friendly VersionMerrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Sep 06, 2005Printer Friendly VersionBear Stearns 18th Annual Healthcare Conference to Webcast Millennium Presentation
Sep 02, 2005Printer Friendly VersionNewsMakers in the Biotech Industry Conference to Webcast Millennium Presentation
Sep 01, 2005Printer Friendly VersionThomas Weisel Partners Healthcare Tailwinds Conference 2005 to Webcast Millennium Presentation
Aug 18, 2005Printer Friendly VersionMillennium Initiates Phase II Clinical Trial to Evaluate MLN1202 in Cardiovascular Disease
Aug 15, 2005Printer Friendly VersionMore Options, More Hope
Aug 15, 2005Printer Friendly VersionMultimedia Available: More Options, More Hope
Jul 28, 2005Printer Friendly VersionMillennium Reports Second Quarter 2005 Financial Results
Jul 22, 2005Printer Friendly VersionSchering-Plough to Acquire From Millennium Exclusive U.S. Marketing Rights for INTEGRILIN® (eptifibatide) Injection
Jul 21, 2005Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Second Quarter Financial Results
Jul 11, 2005Printer Friendly VersionMillennium Initiates Phase II Clinical Trial in Patients With Multiple Sclerosis
Jun 29, 2005Printer Friendly VersionMillennium Announces New CEO
Jun 28, 2005Printer Friendly VersionEARLY ACS Trial Designed to Reinforce Benefit of Early Use of INTEGRILIN® (eptifibatide) Injection in Contemporary nSTE ACS Setting
Jun 17, 2005Printer Friendly VersionMillennium Announces Appointment to Board of Directors
Jun 16, 2005Printer Friendly VersionNew England Journal of Medicine Publishes Studies of VELCADE® (bortezomib) for Injection in Multiple Myeloma and MLN02 in Ulcerative Colitis
Jun 13, 2005Printer Friendly VersionVELCADE® (bortezomib) for Injection Showed Positive Activity Across a Variety of Lymphomas
Jun 10, 2005Printer Friendly VersionGoldman Sachs Twenty-Sixth Annual Global Healthcare Conference to Webcast Millennium Presentation
Jun 08, 2005Printer Friendly VersionTwo New Studies in the British Journal of Haematology Show Potential Role of VELCADE® (Bortezomib) for Injection in Treating Patients with Front-Line Multiple Myeloma
May 17, 2005Printer Friendly VersionNew Front-Line Data at ASCO in Multiple Myeloma Support Important Role of VELCADE® (bortezomib) for Injection
May 14, 2005Printer Friendly VersionMillennium Reports Positive Data for VELCADE® (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented
May 11, 2005Printer Friendly VersionBanc of America Securities Health Care Conference 2005 to Webcast Millennium Presentation
May 09, 2005Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event
May 05, 2005Printer Friendly VersionRobert W. Baird & Co. 2005 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation
Apr 28, 2005Printer Friendly VersionMillennium Pharmaceuticals to Webcast 2005 Annual Meeting of Stockholders
Apr 28, 2005Printer Friendly VersionMillennium Reports First Quarter VELCADE® (bortezomib) for Injection Sales Up 51%, R&D Expenses Down 11% Compared to First Quarter 2004
Apr 25, 2005Printer Friendly VersionVELCADE® (bortezomib) for Injection Phase II Clinical Trial Initiated in Lung Cancer
Apr 21, 2005Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on First Quarter Financial Results
Apr 13, 2005Printer Friendly VersionStudies of VELCADE® (bortezomib) for Injection Show Emerging Role as Cornerstone of Multiple Myeloma Care
Apr 08, 2005Printer Friendly VersionKey Data on VELCADE® (Bortezomib) for Injection in Front-Line Studies and Beyond at the International Multiple Myeloma Workshop
Mar 28, 2005Printer Friendly VersionCIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference to Webcast Millennium Presentation
Mar 28, 2005Printer Friendly VersionMillennium to Discuss Full Approval of VELCADE® (bortezomib) for Injection in Second-Line Multiple Myeloma
Mar 25, 2005Printer Friendly VersionFDA Grants Full Approval for VELCADE® (Bortezomib) for Injection; Claims Include Survival Advantage and Use in Second-Line Multiple Myeloma
Mar 24, 2005Printer Friendly VersionLehman Brothers Eighth Annual Global Healthcare Conference to Webcast Millennium Presentation
Mar 22, 2005Printer Friendly VersionCitigroup Smith Barney Healthcare Conference to Webcast Millennium Presentation
Mar 14, 2005Printer Friendly VersionMillennium Announces Senior Executive Appointments --Expands Key Leadership Roles and Promotes Senior Leaders From Within--
Mar 10, 2005Printer Friendly VersionSG Cowen & Co. 25th Annual Healthcare Conference to Webcast Millennium Presentation
Mar 10, 2005Printer Friendly VersionVelcade® (bortezomib) for Injection Multiple Myeloma Retreatment Clinical Trial Initiated
Mar 08, 2005Printer Friendly VersionData Support the Positive Clinical Benefits of GP IIb-IIIa Inhibitors and INTEGRILIN(R) (eptifibatide) Injection
Mar 07, 2005Printer Friendly VersionMillennium Achieves Milestone Payments of Approximately $40 Million
Mar 01, 2005Printer Friendly VersionINTEGRILIN(R) (Eptifibatide) Injection When Added to Clopidogrel Provided Superior Platelet Inhibition and Reduced Heart Muscle Death, Based on the Release of Cardiac Necrosis Biomarkers
Feb 22, 2005Printer Friendly VersionMillennium to Participate in the SunTrust Robinson Humphrey 'Off the Cuff' Therapeutics Conference
Feb 20, 2005Printer Friendly VersionMillennium Announces Promising Findings from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial
Feb 03, 2005Printer Friendly VersionMerrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
Feb 01, 2005Printer Friendly VersionVELCADE® (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Non-Hodgkin's Lymphoma
Jan 27, 2005Printer Friendly VersionMillennium Reports Year End and Fourth Quarter 2004 Financial Results
Jan 25, 2005Printer Friendly VersionMillennium and UCB Pharma Enter Into Agreement to Collaborate on Two Biotherapeutic Inflammation Programs
Jan 20, 2005Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Fourth Quarter and Full-Year 2004 Financial Results
Jan 10, 2005Printer Friendly VersionMillennium to Highlight 2004 Accomplishments and 2005 Outlook at JPMorgan 23rd Annual Healthcare Conference
Jan 10, 2005Printer Friendly VersionVELCADE® (bortezomib) for Injection Phase III Clinical Trial Initiated In Patients With Newly Diagnosed Multiple Myeloma
Jan 06, 2005Printer Friendly VersionMillennium to Webcast Business Update Conference Call on January 10, 2005 in Advance of JP Morgan Conference Presentation
Jan 05, 2005Printer Friendly VersionJP Morgan 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Dec 20, 2004Printer Friendly VersionMillennium Announces Changes in Commercial Management and Board of Directors
Dec 15, 2004Printer Friendly VersionMillennium Receives Top Industry Awards
Dec 14, 2004Printer Friendly VersionGroundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis Disease Severity
Dec 06, 2004Printer Friendly VersionVELCADE® (Bortezomib) for Injection Studies Results Indicate Potential Utility Across the Multiple Myeloma Treatment Paradigm
Dec 06, 2004Printer Friendly VersionVELCADE® (bortezomib) for Injection Continues to Provide Responses In Several Subtypes of Non-Hodgkin's Lymphoma
Dec 01, 2004Printer Friendly VersionFDA Accepts sNDA Filing with Priority Review for VELCADE® (bortezomib) for Injection to Treat Second-Line Multiple Myeloma
Dec 01, 2004Printer Friendly VersionNew Data on VELCADE® (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting
Nov 29, 2004Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event Monday, December 6, 2004 7:00 P.M. PST (10:00 P.M. EST)
Nov 23, 2004Printer Friendly VersionLazard Annual Life Sciences Conference to Webcast Millennium Presentation
Nov 09, 2004Printer Friendly VersionMillennium Announces Webcast of R&D Day 2004 Presentations
Nov 08, 2004Printer Friendly VersionNew Clinical Trial Data Showed the Addition of INTEGRILIN® (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone
Nov 06, 2004Printer Friendly VersionNew Data Reveal Clinical Differences Between INTEGRILIN ® (Eptifibatide) Injection and Bivalirudin
Nov 03, 2004Printer Friendly VersionCIBC World Markets Fifteenth Annual Healthcare Conference to Webcast Millennium Presentation
Nov 02, 2004Printer Friendly VersionFDA Grants VELCADE® (bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma
Oct 28, 2004Printer Friendly VersionCorrection -- Millennium Pharmaceuticals, Inc.
Oct 28, 2004Printer Friendly VersionMillennium Reports Third Quarter 2004 Financial Results;
Oct 20, 2004Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Third Quarter 2004 Financial Results
Oct 18, 2004Printer Friendly VersionMillennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis
Oct 14, 2004Printer Friendly VersionMillennium Files Post-Effective Amendment to S-3 Registration Statement
Oct 05, 2004Printer Friendly VersionMillennium Appoints New General Counsel
Sep 29, 2004Printer Friendly VersionMillennium Files Supplemental New Drug Application for VELCADE® (bortezomib) for Injection for the Treatment of Patients with Second-Line Multiple Myeloma
Sep 20, 2004Printer Friendly VersionUBS Global Life Sciences Conference to Webcast Millennium Presentation
Sep 14, 2004Printer Friendly VersionBanc of America Securities 34th Annual Investment Conference to Webcast Millennium Presentation
Sep 07, 2004Printer Friendly VersionNewsmakers in the Biotech Industry Conference to Webcast Millennium Presentation
Aug 18, 2004Printer Friendly VersionVELCADE® (bortezomib) for Injection Named Oncology Compound of the Year at the 2004 Pharmaceutical Achievement Awards
Jul 29, 2004Printer Friendly VersionMillennium Appoints Marsha Fanucci Chief Financial Officer
Jul 22, 2004Printer Friendly VersionMillennium Reports Second Quarter 2004 Financial Results
Jul 16, 2004Printer Friendly VersionMillennium Pharmaceuticals to Webcast Conference Call on Second Quarter 2004 Financial Results
Jun 23, 2004Printer Friendly VersionMillennium and GlaxoSmithKline Announce INTEGRILIN® (eptifibatide) Injection Licensing Agreement for Europe
Jun 06, 2004Printer Friendly VersionMillennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer
Jun 06, 2004Printer Friendly VersionVELCADE® (bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients with Previously Untreated Multiple Myeloma
Jun 05, 2004Printer Friendly VersionVELCADE® (Bortezomib) for Injection Data Show a Significant Improvement In Survival in Patients With Relapsed Multiple Myeloma
Jun 02, 2004Printer Friendly VersionGoldman Sachs Twenty Fifth Annual Global Healthcare Conference to Webcast Millennium Presentation
Jun 02, 2004Printer Friendly VersionMillennium Acquires Rights to Novel Proteasome Inhibitors and Related Synthesis Techonology
Jun 01, 2004Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society Of Clinical Oncology Investor Event
Jun 01, 2004Printer Friendly VersionMillennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN(R) (eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting
May 17, 2004Printer Friendly VersionMillennium Announces VELCADE(R) (bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients with Relapsed Multiple Myeloma
May 13, 2004Printer Friendly VersionBanc of America Securities Health Care Conference 2004 to Webcast Millennium Presentation
May 13, 2004Printer Friendly VersionMillennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma
Apr 30, 2004Printer Friendly VersionMillennium Pharmaceuticals to Webcast 2004 Annual Meeting of Stockholders
Apr 28, 2004Printer Friendly VersionMillennium Reports First Quarter 2004 Financial Results
Apr 27, 2004Printer Friendly VersionEuropean Commission Grants Marketing Authorization to Millennium for VELCADE(R) (Bortezomib)
Apr 22, 2004Printer Friendly VersionMillennium Pharmaceuticals To Webcast Conference Call on First Quarter 2004 Financial Results
Apr 01, 2004Printer Friendly VersionMillennium and NCI Collaborate to Investigate Role of ACE2 in Connection with SARS
Mar 17, 2004Printer Friendly VersionMillennium Announces FDA Selection of MLN2704 for Continuous Marketing Application Pilot 2 Program
Mar 02, 2004Printer Friendly VersionSG Cowen 24th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Feb 25, 2004Printer Friendly VersionLehman Brothers Seventh Annual Global Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Jan 27, 2004Printer Friendly VersionMillennium Reports Year End and Fourth Quarter 2003 Financial Results
Jan 22, 2004Printer Friendly VersionVELCADE(TM) (Bortezomib) Recommended for European Marketing Approval
Jan 20, 2004Printer Friendly VersionMillennium Pharmaceuticals, Inc. to Webcast Conference Call on Year End And Fourth Quarter 2003 Financial Results on January 28, 2004
Jan 12, 2004Printer Friendly VersionMillennium to Highlight 2004 Financial Outlook and Goals at JPMorgan Healthcare Conference
Jan 06, 2004Printer Friendly VersionMillennium Responds to Media Reports Related to Closure Of Phase II VELCADE Colorectal Trial
Jan 05, 2004Printer Friendly VersionJP Morgan 22nd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Dec 22, 2003Printer Friendly VersionMillennium Initiates Phase I Clinical Trial of MLN3897
Dec 18, 2003Printer Friendly VersionXOMA and Millennium Announce Initiation of Phase I Clinical Trial of MLN2222 -- a.k.a. CAB-2 -- a Novel Complement Inhibitor
Dec 15, 2003Printer Friendly VersionIndependent Committee Recommends Early End to Confirmatory Phase III VELCADE Trial Based on Achieving Statistically Significant Improvement in Primary Endpoint
Dec 11, 2003Printer Friendly VersionEarly Research Advances Field of Proteasome Biology
Dec 09, 2003Printer Friendly VersionPreliminary Study Results of VELCADE(TM) (bortezomib) for Injection Combined With Thalidomide Demonstrated Anti-Tumor Activity in Patients With Advanced Multiple Myeloma
Dec 08, 2003Printer Friendly VersionNew Phase II Findings Support Potential Role of VELCADE(TM) (bortezomib) for Injection in Patients With Non-Hodgkin's Lymphoma
Dec 08, 2003Printer Friendly VersionPreliminary Phase II Results With VELCADE™ (bortezomib) For Injection Demonstrated Activity In Patients With Previously Untreated Multiple Myeloma
Dec 04, 2003Printer Friendly VersionFDA Grants Millennium Fast Track Status for MLN2704
Dec 03, 2003Printer Friendly VersionNew Data on VELCADE(TM) (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting
Dec 01, 2003Printer Friendly VersionMillennium Announces Webcast of American Society of Hematology Investor Event
Nov 04, 2003Printer Friendly VersionCIBC World Markets Fourteenth Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Oct 27, 2003Printer Friendly VersionMillennium and Bayer's Successful Research Collaboration Concludes
Oct 15, 2003Printer Friendly VersionMillennium Reports Third Quarter 2003 Financial Results
Oct 14, 2003Printer Friendly VersionMillennium Initiates Phase II Clinical Trial With MLN1202 in Patients With Rheumatoid Arthritis
Oct 09, 2003Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast Of Analyst And Investor Day Presentations
Oct 09, 2003Printer Friendly VersionMillennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients with Metastatic Androgen-Independent Prostate Cancer
Sep 26, 2003Printer Friendly VersionMillennium Announces Assignment of Medicare Code for VELCADE(TM) (bortezomib) for Injection
Sep 22, 2003Printer Friendly VersionUBS Global Life Sciences Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Sep 19, 2003Printer Friendly VersionCorrection to Press Release: New Data Show Early Use of Anti-Platelet Therapy Reduced Combined Death or Subsequent Heart Attacks in High-Risk Heart Attack Patients
Sep 17, 2003Printer Friendly VersionNew Data Show Early Use Of Anti-Platelet Therapy Reduced Combined Death Or Subsequent Heart Attacks In High-Risk Heart Attack Patients
Aug 28, 2003Printer Friendly VersionNewsmakers in the Biotech Industry Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
Aug 22, 2003Printer Friendly VersionMillennium Announces Changes in R&D Management
Jul 22, 2003Printer Friendly VersionMillennium Reports Second Quarter 2003 Financial Results
Jul 16, 2003Printer Friendly VersionMillennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003
Jul 10, 2003Printer Friendly VersionMillennium Announces Changes in Senior Management
Jul 03, 2003Printer Friendly VersionMillennium and Xenova Initiate Phase I Clinical Trial Of MLN944
Jul 02, 2003Printer Friendly VersionMillennium Initiates Phase II Clinical Trial with VELCADE(TM) (Bortezomib) for Injection in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Jun 30, 2003Printer Friendly VersionMillennium Enters Into Commercialization and Development Agreement With Ortho Biotech Products, L.P., for VELCADE(TM) (Bortezomib) For Injection
Jun 25, 2003Printer Friendly VersionVelcade(TM) (Bortezomib) for Injection Phase II (Summit) Multiple Myeloma Study Results Published in the New England Journal of Medicine
Jun 05, 2003Printer Friendly VersionMillennium Announces Restructuring
Jun 04, 2003Printer Friendly VersionGoldman Sachs Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Jun 03, 2003Printer Friendly VersionMillennium Announces Promising Early Study Results With VELCADE(TM) (bortezomib) For Injection Combined With Doxil in Patients With Advanced Multiple Myeloma
Jun 02, 2003Printer Friendly VersionMillennium Announces Preliminary Phase I and Phase II Findings of VELCADE(TM) (Bortezomib) For Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors
May 27, 2003Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event
May 21, 2003Printer Friendly VersionIn Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo
May 20, 2003Printer Friendly VersionMillennium Ships VELCADE(TM) (bortezomib) for Injection Within Six Days of FDA Approval
May 13, 2003Printer Friendly VersionMedia Relations Conference Call
May 13, 2003Printer Friendly VersionMillennium to Webcast Conference Call on Recent FDA Approval of Velcade(TM) (bortezomib) for Injection on May 14, 2003
May 13, 2003Printer Friendly VersionFDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma
May 06, 2003Printer Friendly VersionRobert W. Baird 2003 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation
Apr 29, 2003Printer Friendly VersionMillennium Announces Completion of Cash Offers For 4.50% and 5.00% Convertible Notes
Apr 29, 2003Printer Friendly Version2003 Deutsche Bank Securities Health Care Conference to Webcast Millennium Pharmaceuticals Presentation
Apr 24, 2003Printer Friendly VersionMorgan Stanley 1st Annual Healthcare Unplugged Conference to Webcast Millennium Pharmaceuticals Presentation
Apr 24, 2003Printer Friendly VersionMillennium Pharmaceuticals to Webcast 2003 Annual Meeting of Stockholders
Apr 23, 2003Printer Friendly VersionCIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals Presentation
Apr 21, 2003Printer Friendly VersionMillennium Confirms Terms of Convertible Notes
Apr 15, 2003Printer Friendly VersionMillennium Reports First Quarter 2003 Financial Results
Apr 14, 2003Printer Friendly VersionGroundbreaking Research Identifies Molecular Pathway Underlying Key Infection-Fighting Mechanism
Apr 09, 2003Printer Friendly VersionMillennium to Webcast Conference Call on First Quarter 2003 Financial Results on April 15, 2003
Mar 31, 2003Printer Friendly VersionMillennium Commences Required Cash Offers for Convertible Notes
Mar 20, 2003Printer Friendly VersionBanc of America Securities Healthcare Conference 2003 to Webcast Millennium Pharmaceuticals Presentation
Mar 13, 2003Printer Friendly VersionSG Cowen 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentations
Mar 10, 2003Printer Friendly VersionFDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection
Feb 25, 2003Printer Friendly VersionEMEA Accepts Marketing Authorization Application For Bortezomib (VELCADE(TM)) 3.5mg Powder For Solution For Injection
Feb 24, 2003Printer Friendly VersionLehman Brothers Sixth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals Presentation
Feb 19, 2003Printer Friendly VersionBio CEO & Investor Conference 2003 to Webcast Millennium Pharmaceuticals Presentation
Feb 04, 2003Printer Friendly VersionMillennium Seeks European Regulatory Approval for Bortezomib (VELCADE(TM)) 3.5mg Powder for Solution for Injection
Jan 28, 2003Printer Friendly VersionMillennium Reports Year End and Fourth Quarter 2002 Financial Results
Jan 22, 2003Printer Friendly VersionMillennium to Webcast Conference Call on Year End and Fourth Quarter 2002 Financial Results On January 28, 2003
Jan 22, 2003Printer Friendly VersionMillennium Submits New Drug Application for VELCADE(TM) (Bortezomib) for Injection
Jan 15, 2003Printer Friendly VersionMillennium Initiates Phase II Clinical Trial With Velcade(TM) (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer
Jan 06, 2003Printer Friendly VersionMillennium Highlights 2003 Financial Outlook and Goals at JP Morgan H&Q Healthcare Conference
Dec 30, 2002Printer Friendly VersionJP Morgan H&Q 21st Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Dec 30, 2002Printer Friendly VersionMillennium Initiates Phase II Clinical Trial With VELCADE™ (Bortezomib) for Injection in Patients With Colorectal Cancer
Dec 20, 2002Printer Friendly VersionMillennium Initiates Phase I Clinical Trial of MLN1021, A Novel, Oral Factor Xa Inhibitor
Dec 16, 2002Printer Friendly VersionMillennium Initiates Phase I Clinical Trial of MLN1202
Dec 11, 2002Printer Friendly VersionMillennium Discovers Markers Associated With Chemotherapy Response in Breast Cancer Patients
Dec 09, 2002Printer Friendly VersionFinal Phase II Data Presented from the VELCADE™ (bortezomib) for Injection Summit Trial in Patients with Advanced Stage Multiple Myeloma
Dec 09, 2002Printer Friendly VersionNew Data From Velcade™ (Bortezomib) For Injection Crest Study Indicate Responses In Patients With Relapsed Multiple Myeloma
Dec 04, 2002Printer Friendly VersionMillennium Announces Changes in Senior Management
Dec 04, 2002Printer Friendly VersionMillennium To Host Conference Call And Webcast
Dec 04, 2002Printer Friendly VersionMillennium Plans To Submit a New Drug Application for Velcade™ (Bortezomib) for Injection
Dec 02, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
Nov 21, 2002Printer Friendly VersionMillennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
Nov 19, 2002Printer Friendly VersionMillennium Announces Cardiovascular Research Collaboration With The Cleveland Clinic
Nov 17, 2002Printer Friendly VersionNew Data Show Hospital Adherence to Chest Pain Guidelines Reduced Risk of Death by Nearly Half
Nov 12, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of American Heart Association Scientific Sessions Investor Event Presentations
Nov 11, 2002Printer Friendly VersionMillennium Announces Initiation of Phase III Clinical Trial of INTEGRILIN® (eptifibatide) Injection in Heart Attack Patients
Nov 07, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At Credit Suisse First Boston Health Care Conference
Nov 04, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at SG Cowen Global 2002 Health Care Conference
Oct 30, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at CIBC World Markets 13th Annual Health Care Conference
Oct 22, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at MassOpps 4th Annual Investor Conference
Oct 20, 2002Printer Friendly Version77 Per Cent of Multiple Myeloma Patients Showed Reduction or Stabilisation in Myeloma -M- Protein Levels in Preliminary Phase II Data for Proteasome Inhibitor Bortezomib
Oct 15, 2002Printer Friendly VersionMillennium Reports Third Quarter 2002 Financial Results
Oct 09, 2002Printer Friendly VersionMillennium to Webcast Conference Call on Third Quarter 2002 Financial Results on October 15, 2002
Oct 03, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At UBS Warburg Global Life Sciences Conference
Sep 16, 2002Printer Friendly VersionMillennium Announces Phase II Data for MLN02 in Crohn's Disease
Sep 10, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Bear Stearns 15th Annual Health Care Conference
Jul 16, 2002Printer Friendly VersionMillennium Reports Second Quarter 2002 Financial Results
Jul 15, 2002Printer Friendly VersionMillennium Discontinues Oral MLN977 Program
Jul 10, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast Of Oncology Franchise Review Presentations
Jul 10, 2002Printer Friendly VersionMillennium to Webcast Conference Call On Second Quarter 2002 Financial Results On July 16, 2002
Jun 11, 2002Printer Friendly VersionMillennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE™ (bortezomib) for Injection with High-Dose Dexamethasone in Patients with Multiple Myeloma
Jun 05, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast Of Presentation at the Goldman Sachs 23rd Annual Global Healthcare Conference
May 29, 2002Printer Friendly VersionMillennium Initiates Phase I Clinical Trial of MLN518 In Acute Myeloid Leukemia (AML)
May 28, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At the Needham & Company First Annual Biotechnology Conference
May 21, 2002Printer Friendly VersionMillennium Researchers Announce Preliminary Phase I Findings of Proteasome Inhibitor MLN341 Against Several Solid Tumor Types
May 20, 2002Printer Friendly VersionPreliminary Phase II Data on Millennium's Proteasome Inhibitor MLN341 Hold Promise for Patients With Multiple Myeloma
Apr 30, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the Deutsche Bank Securities 27th Annual Health Care Conference
Apr 29, 2002Printer Friendly VersionMillennium Announces Completion of Cash Offer For Notes Assumed in COR Therapeutics Merger
Apr 24, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Apr 23, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Panel Discussion at The Thomas Weisel Healthcare Tailwinds Conference
Apr 22, 2002Printer Friendly VersionMillennium Amends Notes Assumed in COR Therapeutics Merger
Apr 16, 2002Printer Friendly VersionMillennium Reports First Quarter 2002 Financial Results
Apr 16, 2002Printer Friendly VersionMillennium Pharmaceuticals and Ingenuity Systems Announce Groundbreaking Knowledge Management Collaboration
Apr 12, 2002Printer Friendly VersionMillennium to Webcast Conference Call on First Quarter 2002 Financial Results on April 16, 2002
Apr 09, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at The Nasdaq European Life Sciences Forum
Apr 08, 2002Printer Friendly VersionMillennium Researchers Announce Preclinical Findings of its Proteasome Inhibitor MLN341 Against Several Solid Tumor Types
Mar 28, 2002Printer Friendly VersionSEC Declares Effective Registration Statement of Millennium Pharmaceuticals Related to 4.50% Convertible Senior Notes
Mar 27, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Fourth Annual Analyst and Investor Day Presentations
Mar 14, 2002Printer Friendly VersionMillennium Announces Cash Offers for Notes Assumed in COR Therapeutics, Inc. Merger
Mar 14, 2002Printer Friendly VersionMillennium and PAION to Collaborate on Stroke Program
Mar 13, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Panel Discussion and Presentation at The Banc of America Genomics & Diagnostics Conference
Feb 15, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the Bio CEO & Investor Conference
Feb 14, 2002Printer Friendly VersionMillennium's Chief Scientific Officer Appointed to National Advisory Council for Human Genome Research
Feb 14, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Panel Discussions at The Goldman Sachs Oncology Conference
Feb 12, 2002Printer Friendly VersionShareholders Approve Merger of Millennium Pharmaceuticals and COR Therapeutics
Jan 31, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the Merrill Lynch Global Drug, Device and Biotech Conference
Jan 24, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the U.S. Bancorp Piper Jaffray Health Care Conference
Jan 22, 2002Printer Friendly VersionMillennium Reports Year End 2001 Financial Results
Jan 17, 2002Printer Friendly VersionMillennium and COR Therapeutics Receive Early Hart-Scott-Rodino Clearance
Jan 15, 2002Printer Friendly VersionMillennium to Webcast Conference Call on Year End 2001 Financial Results on January 22, 2002
Jan 09, 2002Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at the Wachovia Securities Integrated Oncology Conference
Jan 07, 2002Printer Friendly VersionMillennium Highlights Financial Outlook and Goals for 2002 at JPMorgan H&Q Healthcare Conference
Jan 07, 2002Printer Friendly VersionMillennium Initiates Combination Oncology Trials of MLN341 with Taxotere®
Jan 03, 2002Printer Friendly VersionJP Morgan H&Q 20th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Dec 17, 2001Printer Friendly VersionMillennium In-Licenses Novel Oncology Program From Xenova
Dec 10, 2001Printer Friendly VersionNew Phase II Data on Millennium's Proteasome Inhibitor Holds Promise For Patients With Refractory Multiple Myeloma
Dec 06, 2001Printer Friendly VersionMillennium and COR Therapeutics Agree to Merge Creating Integrated Biopharmaceutical Company
Nov 27, 2001Printer Friendly VersionMillennium and Abbott Initiate Phase I Trials of Their First Genomically-Derived Drug Target for Obesity
Nov 26, 2001Printer Friendly VersionMillennium In-Licenses Novel Target for Colorectal Cancer
Nov 26, 2001Printer Friendly VersionMillennium and XOMA Enter Agreement to Collaborate on Two Vascular Inflammation Programs
Nov 20, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At the SG Cowen Investor Conference
Nov 20, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Posting of Presentation at The Robertson Stephens Healthcare Conference on its Website
Nov 02, 2001Printer Friendly VersionMillennium Researchers Announce Initial Findings of Phase I Trial of Proteasome Inhibitor for Multiple Myeloma
Nov 01, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at CIBC World Markets Health Care Conference
Oct 29, 2001Printer Friendly VersionILEX and Millennium Agree to Restructure Ownership in Campath(R)
Oct 24, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at The Mass Opportunities Investor Conference
Oct 24, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at The Salomon Smith Barney Health Care Conference
Oct 24, 2001Printer Friendly VersionMillennium and Affymetrix Partner to Advance Gene Expression Array Technology
Oct 19, 2001Printer Friendly VersionMillennium and New York Weill Cornell Medical Center Researchers Report Interim Findings of Ongoing Phase I Human Clinical Trials of a Humanized Antibody Therapy for Advanced Prostate Cancer
Oct 16, 2001Printer Friendly VersionMillennium Reports Third Quarter 2001 Financial Results
Oct 16, 2001Printer Friendly VersionMillennium Researchers Identify New Role for Collagenase Enzyme in Cardiovascular Disease
Oct 12, 2001Printer Friendly VersionMillennium to Webcast Conference Call on Third Quarter 2001 Financial Results on October 16, 2001
Oct 11, 2001Printer Friendly VersionMillennium Names Allan Marchington, Ph.D., Senior Vice President Of Productivity
Oct 04, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At the UBS Warburg Global Life Sciences Conference
Oct 04, 2001Printer Friendly VersionMillennium Completes Enrollment of a Phase II Human Clinical Trial for LDP-341 in Multiple Myeloma
Oct 03, 2001Printer Friendly VersionMillennium Expands Proteasome Patent Estate
Sep 24, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At Bear Stearns Health Care 'Virtual' Conference
Sep 19, 2001Printer Friendly VersionBayer and Millennium Expand Commitment Based on Success of Research Program and Advancements In Drug Discovery
Sep 07, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Banc of America Securities Annual Investment Conference
Sep 07, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Bear Stearns 14th Annual Health Care Conference
Aug 13, 2001Printer Friendly VersionAventis Pharma And Millennium Add 11 Discovery Projects To Joint Drug Development Pipeline For Inflammatory Disease
Jul 17, 2001Printer Friendly VersionMillennium Reports Second Quarter 2001 Financial Results
Jul 17, 2001Printer Friendly VersionMillennium and Pharsight Sign Agreement for Application Of Pharsight's Model- Based Software and Methodologies to Millennium's Head Oncology Program
Jul 12, 2001Printer Friendly VersionEuropean Commission Grants Marketing Authorization To Millennium & ILEX Partners' MabCampath(TM) (Alemtuzumab
Jul 11, 2001Printer Friendly VersionMillennium to Webcast Conference Call on Second Quarter 2001 Financial Results on July 18, 2001
Jul 09, 2001Printer Friendly VersionBiomax Informatics AG Licenses the BioRS Integration and Retrieval Plus System to Millennium Pharmaceuticals, Inc.
Jun 22, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at First Union Securities Eleventh Annual Nantucket Equity Conference
Jun 15, 2001Printer Friendly VersionMillennium Initiates Phase II Clinical Trials of LDP-341 in Chronic Lymphocytic Leukemia
Jun 14, 2001Printer Friendly VersionMillennium Initiates Combination Trials of LDP-341 With Gemcitabine and Irinotecan
Jun 13, 2001Printer Friendly VersionMillennium Promotions Strengthen Management Team and Enhance Organizational Effectiveness
Jun 12, 2001Printer Friendly VersionMillennium Initiates Phase II Clinical Trial of LDP-977 in Asthma
Jun 07, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Goldman Sachs Healthcare Conference
May 08, 2001Printer Friendly VersionU.S. Food and Drug Administration Approves New Treatment, Campath(R) (alemtuzumab) Humanized Monoclonal Antibody, for Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL
May 02, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Deutsche Banc Alex. Brown Health Care Conference
Apr 19, 2001Printer Friendly VersionMillennium Names Peter F. Smith Senior Vice President of Preclinical Drug Development
Apr 17, 2001Printer Friendly VersionMillennium Reports First Quarter 2001 Financial Results
Apr 11, 2001Printer Friendly VersionMillennium to Webcast Conference Call on First Quarter 2001 Financial Results on April 18, 2001
Apr 11, 2001Printer Friendly VersionMillennium and BZL Biologics Announce Agreement To Develop Antibody Therapies Against Key Target In Prostate Cancer
Apr 05, 2001Printer Friendly VersionMillennium Pharmaceuticals Adopts Shareholder Rights Plan
Apr 02, 2001Printer Friendly VersionMillennium Appoints Kenneth E. Weg, Former Vice Chairman of Bristol-Myers Squibb, to Board of Directors
Mar 30, 2001Printer Friendly VersionMabCampath(TM) (Alemtuzumab) Recommended For European Marketing Approval
Mar 30, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Third Annual Analyst and Investor Day Presentations
Mar 22, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation At Banc of America Securities Health Care Conference
Mar 13, 2001Printer Friendly VersionMillennium and Protein Design Labs Announce Agreement For Humanized Antibody Patent Rights
Mar 12, 2001Printer Friendly VersionMillennium and Abbott Laboratories Form Strategic Alliance in Metabolic Disease
Mar 05, 2001Printer Friendly VersionMillennium and ImmunoGen Form Multi-Product Antibody Collaboration
Mar 01, 2001Printer Friendly VersionMillennium Initiates Phase II Clinical Trials of LDP-341 in Multiple Myeloma
Feb 27, 2001Printer Friendly VersionMillennium Pharmaceuticals Presentation to Lehman Brothers Global Healthcare Conference to be Available by Conference Call
Feb 27, 2001Printer Friendly VersionMillennium Issued Broad Patent for ACE2 Gene Which Holds Potential For Targeted Disease Management
Feb 21, 2001Printer Friendly VersionMillennium & ILEX Partners Receives Complete Response Letter From FDA for CAMPATH(R) (Alemtuzumab
Feb 08, 2001Printer Friendly VersionMillennium Initiates Phase II Clinical Trial of LDP-02 In Ulcerative Colitis
Feb 02, 2001Printer Friendly VersionMillennium Pharmaceuticals Announces Webcast of Presentation at Merrill Lynch Global Pharmaceutical Device and Biotechnology Conference
Jan 23, 2001Printer Friendly VersionMillennium Reports Year End 2000 Financial Results - Provides 2001 Financial Guidance
Jan 17, 2001Printer Friendly VersionMillennium to Webcast Conference Call on Year End 2000 Financial Results on January 24, 2001
Jan 12, 2001Printer Friendly VersionStudy Validates That Melastatin(TM) Gene Assists With Prognosis Of Melanoma
Jan 10, 2001Printer Friendly VersionMillennium and Bayer Announce Genome-Derived Oncology Drug Candidate Selected for First Human Studies
Jan 09, 2001Printer Friendly VersionMillennium and Wyeth-Ayerst Identify Preclinical Antibacterial Compound
Jan 08, 2001Printer Friendly VersionMillennium and Roche Form Alliance in the Area of Rheumatoid Arthritis Diagnostics
Jan 05, 2001Printer Friendly VersionChase H&Q 19th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
Jan 04, 2001Printer Friendly VersionMillennium Names Paul Hamelin Senior Vice President of Commercial Operations
Dec 12, 2000Printer Friendly VersionMillennium to Webcast Conference Call Following Review of CAMPATH Data by FDA Advisory Committee
Dec 04, 2000Printer Friendly VersionMillennium's LDP(PS)-341 Inhibits Growth and Induces Death of Cancer Cells, Appears to Overcome Chemotherapy Resistance
Nov 22, 2000Printer Friendly VersionMillennium Appoints Edward Miller, CEO and Dean of Johns Hopkins Medicine, To Board of Directors
Nov 09, 2000Printer Friendly VersionMillennium's LDP-341 Demonstrates Encouraging Anti-Cancer Activity In Clinical Trials
Oct 17, 2000Printer Friendly VersionMillennium Reports Third Quarter 2000 Financial Results
Sep 29, 2000Printer Friendly VersionMillennium Offering Shares of Its Common Stock
Sep 26, 2000Printer Friendly VersionMillennium Names James A. Nash Senior Vice President of Manufacturing
Sep 07, 2000Printer Friendly VersionMillennium's Board Approves Two-For-One Stock Split
Aug 09, 2000Printer Friendly VersionMillennium Expands Global Presence Through Opening of Japan Office
Jun 01, 2000Printer Friendly VersionMillennium Names Susan Ward To Senior Management Team
Apr 18, 2000Printer Friendly VersionMillennium Reports First Quarter 2000 Financial Results - Two-for-one Stock Split Effective
Apr 07, 2000Printer Friendly VersionChristopher Mirabelli, Ph.D. to Resign From Millennium Following Completion Of His Role in Integration of LeukoSite
Mar 27, 2000Printer Friendly VersionMillennium Technology Platform Expands to Include LabChip Tools Through Collaboration with Caliper
Mar 20, 2000Printer Friendly VersionMillennium Extends Collaboration With MorphoSys AG to Advance an Additional Antibody Target
Mar 15, 2000Printer Friendly VersionMillennium's Commercialization Strategy Enhanced Through Wide Access to Human Genome
Mar 06, 2000Printer Friendly VersionMillennium Gains Broad Access To Human Antibody Technology Through Collaboration With Abgenix
Feb 28, 2000Printer Friendly VersionMillennium's Board Approves Two-For-One Stock Split
Feb 03, 2000Printer Friendly VersionMillennium and Wyeth-Ayerst Announce The Discovery of Key Potassium Ion Channel Modulating Proteins In The Journal Nature
Jan 25, 2000Printer Friendly VersionMillennium Reports Fourth Quarter and Year End 1999 Financial Results Including One-Time Acquisition Related Charges
Dec 23, 1999Printer Friendly VersionILEX Oncology and Millennium Submit Biologics License Application (BLA) for CAMPATH(R)
Dec 22, 1999Printer Friendly VersionMillennium Announces the Completion of LeukoSite and Millennium BioTherapeutics Mergers
Dec 20, 1999Printer Friendly VersionMillennium Delivers Validated Target in Prostate Cancer for Screening to Eli Lilly
Dec 07, 1999Printer Friendly VersionMillennium Issued Broad Patent Relating to the Leptin Receptor and Body Weight Regulation
Nov 30, 1999Printer Friendly VersionMillennium and LeukoSite Receive Early Hart-Scott-Rodino Clearance
Nov 11, 1999Printer Friendly VersionBristol-Myers Squibb and Millennium Predictive Medicine Establish Unique Pharmacogenomics Alliance in Cancer Treatment
Oct 19, 1999Printer Friendly VersionMarcia Radosevich Appointed to the Board of Directors of Millennium Predictive Medicine
Oct 15, 1999Printer Friendly VersionMillennium Reports Third Quarter 1999 Financial Results
Oct 05, 1999Printer Friendly VersionMillennium Forms Agreements With Incyte and Lexicon Genetics For Access to Genomic Databases
Sep 29, 1999Printer Friendly VersionMillennium and Bayer Achieve Significant Progess in Major Research Alliance
Aug 31, 1999Printer Friendly VersionMillennium Announces Extension of Central Nervous System Research Collaboration With Wyeth-Ayerst
Aug 16, 1999Printer Friendly VersionMillennium Appoints Joseph Bolen, Ph.D. as Vice President of Oncology
Jul 20, 1999Printer Friendly VersionMillennium Reports Second Quarter 1999 Financial Results
Jul 01, 1999Printer Friendly VersionWhitehead Functional Genomics Consortium Announces Technology Contribution To SNP Consortium
Jun 15, 1999Printer Friendly VersionMillennium Outlines Growth Strategy at Goldman Sachs Healthcare Conference
Jun 01, 1999Printer Friendly VersionMillennium Names Jack Douglas General Counsel
May 18, 1999Printer Friendly VersionMillennium Receives U.S. Patent for Polycystic Kidney Disease Diagnostic Tests
Apr 20, 1999Printer Friendly VersionMillennium Reports First Quarter 1999 Financial Results
Mar 23, 1999Printer Friendly VersionPartners HealthCare and Millennium Establish Broad Strategic Research Collaboration
Mar 18, 1999Printer Friendly VersionMillennium Delivers Seventh Antibacterial drug Target For Screening To Wyeth-ayerst
Mar 10, 1999Printer Friendly VersionMillennium Clones Diet-induced Obesity Gene
Feb 22, 1999Printer Friendly VersionMillennium Predictive Medicine and Becton Dickinson Establish Research Alliance in Diagnostics Industry
Feb 09, 1999Printer Friendly VersionMillennium Reports Fourth Quarter And Year End 1998 Financial Results
Feb 09, 1999Printer Friendly VersionMillennium Awarded U.S. Patent Relating To Methods For Discovering New Obesity Drugs
Feb 02, 1999Printer Friendly VersionMillennium Awarded Broad U.S. Patent Covering Methods For Identifying Antimicrobial Drug Targets
Jan 12, 1999Printer Friendly VersionMillennium Extends Three Pharmaceutical Corporate Partnerships; Reinforces Millennium's Value In The Drug Discovery Process
Jan 05, 1999Printer Friendly VersionMillennium Announces Several Key Management Appointments Supporting Advancement Toward Commercialization; Kevin Starr Named Chief Financial Officer
Dec 22, 1998Printer Friendly VersionMillennium Awarded U.S. Patents For Two Novel Caspase Genes
Dec 21, 1998Printer Friendly VersionMillennium Delivers Two Cardiovascular Drug Targets For Screening To Eli Lilly
Dec 21, 1998Printer Friendly VersionMillennium Biotherapeutics And Harvard Medical School Develop Unique Approach To Streamline Collaboration And Share Novel Genes
Dec 15, 1998Printer Friendly VersionMillennium Awarded Two U.S. Patents Covering Novel Genes Involved In TGF-Beta Signaling Pathways
Dec 14, 1998Printer Friendly VersionMillennium Delivers Two Cardiovascular
Nov 04, 1998Printer Friendly VersionMillennium Delivers Sixth Antibacterial Drug Target For Screening to Wyeth-Ayerst
Sep 24, 1998Printer Friendly VersionMillennium Reaches Over $1 Billion in Total Pharmaceutical Alliance Funding
Sep 24, 1998Printer Friendly VersionMillennium and Bayer Form World's Largest Drug Discover Alliance in the Pharmaceutical Industry
Aug 11, 1998Printer Friendly VersionMillennium Reports Second Quarter 1998 Financial Results
Aug 10, 1998Printer Friendly VersionMillennium and M. D. Anderson Cancer Center Establish Clinical Collaboration
Aug 10, 1998Printer Friendly VersionMillennium and the University of Pittsburgh Announce Tissue Bank Collaboration
Aug 10, 1998Printer Friendly VersionMillennium Aligns With Two Key Biomedical Research Institutions As Part Of Broad Strategy For Genomics-Based Drug Discovery And Development
Jul 15, 1998Printer Friendly VersionAbgenix and Millennium BioTherapeutics Form Collaboration Collaboration Marks Fifth Corporate Deal for Abgenix and Start Of Development for Millennium BioTherapeutic's First Clinical Candidate
Jul 13, 1998Printer Friendly VersionMillennium and Wyeth-Ayerst Identify Novel Gene Implicated In Disorders of The Central Nervous System
Jun 30, 1998Printer Friendly VersionMillennium Achieves Research Milestone in Obesity
Jun 29, 1998Printer Friendly VersionMillennium and Wyeth-Ayerst Identify Gene That Modulates Key Ion Channel Involved in Disorders of the Central Nervous System
Jun 02, 1998Printer Friendly VersionMillennium Awarded U.S. Patent Covering Novel Methods for Identifying Drug Discovery Targets
May 21, 1998Printer Friendly VersionBiotech Stocks Have Incredible Future And Hold Big Risks, T. Rowe Price Analyst Jenner Advises Investors
May 19, 1998Printer Friendly VersionMillennium Predictive Medicine Announces Addition of Key New Employees